The Japanese Red Cross Nagasaki Genbaku Hospital
About The Japanese Red Cross Nagasaki Genbaku Hospital
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Celgene
8
Bayer
2
Hoffmann-La Roche
2
Allergan
1
BeiGene
1
Eli Lilly and Company
1
Kyowa Kirin Co., Ltd.
1
Regeneron Pharmaceuticals
1
Clinical Trials at The Japanese Red Cross Nagasaki Genbaku Hospital
During the past decade, The Japanese Red Cross Nagasaki Genbaku Hospital conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 6 clinical trials were completed, i.e. on
average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
2010-07-01
2012-04-01
Completed
44
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
2012-11-12
2017-03-21
Completed
26
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
2013-06-27
2020-11-12
Completed
2,877
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
2013-11-21
2022-01-26
Completed
358
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
2015-06-25
2019-06-06
Completed
949
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
2016-10-14
2028-02-02
Recruiting
449
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
2019-01-02
2027-09-28
Active, not recruiting
363
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
2019-02-19
2022-01-18
Completed
671
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "The Japanese Red Cross Nagasaki Genbaku Hospital" #1 sponsor was "Celgene" with 8 trials, followed by "Bayer" with 2 trials
sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Allergan" with 1 trials sponsored and "BeiGene"
with 1 trials sponsored. Other sponsors include -2 different institutions and
companies that sponsored additional 8 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "The Japanese Red Cross Nagasaki Genbaku Hospital"
#1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at The Japanese Red Cross Nagasaki Genbaku Hospital
According to Clinical.Site data, the most researched conditions in "The Japanese Red Cross Nagasaki Genbaku Hospital" are
"Myelodysplastic Syndromes" (3 trials), "Primary Myelofibrosis" (2 trials), "Adult T-Cell Leukemia-Lymphoma" (1 trials), "Adult T-cell Leukemia-Lymphoma" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "The Japanese Red Cross Nagasaki Genbaku Hospital" in a lesser frequency.
Clinical Trials Intervention Types at The Japanese Red Cross Nagasaki Genbaku Hospital
Most popular intervention types in "The Japanese Red Cross Nagasaki Genbaku Hospital" are "Drug" (17 trials), "Other" (3 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (4 trials), "Luspatercept" (3 trials), "Sham Procedure" (3 trials), "Faricimab" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.
Clinical Trials Genders at The Japanese Red Cross Nagasaki Genbaku Hospital
The vast majority of trials in "The Japanese Red Cross Nagasaki Genbaku Hospital" are
17 trials for "All" genders.
Clinical Trials Status at The Japanese Red Cross Nagasaki Genbaku Hospital
Currently, there are NaN active trials in "The Japanese Red Cross Nagasaki Genbaku Hospital".
undefined are not yet recruiting,
5 are recruiting,
5 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 7 completed trials in The Japanese Red Cross Nagasaki Genbaku Hospital,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in The Japanese Red Cross Nagasaki Genbaku Hospital, 3 "Phase 1"
clinical trials were conducted, 9 "Phase 2" clinical
trials and 8 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".